Efficacy of oral Vitamin D therapy in children with Vitamin D deficiency

Comparison of therapeutic response to identical oral Vitamin D between obese and non-obese children with vitamin D deficiency

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2012100210988N1

Enrollment

Registered

2012-11-14

Start date

2012-11-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Vitamin D deficiency. Condition 2: obesity. Vitamin D deficiency, unspecified Obesity, unspecified

Interventions

Intervention 1: 300,000 IU oral Vitamin D in 6 weeks(50,000 IU once a week) in Obese children with Vitamin D deficiency. Intervention 2: 300,000 IU oral Vitamin D in 6 weeks(50,000 IU once a week) in

Treatment - Drugs

300,000 IU oral Vitamin D in 6 weeks(50,000 IU once a week) in Obese children with Vitamin D deficiency

300,000 IU oral Vitamin D in 6 weeks(50,000 IU once a week) in Non obese children with Vitamin D deficiency

Eligibility

Sex/Gender

All

Age

2 Years to 14 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria : Child ; Ages 2-14 years Exclusion criteria: Body Mass Index between 85-95 percentile for age ; Ingestion of vitamin D ; Multivitamin supplements usage ; Anticonvulsants usage ; Systemic corticosteroids usage ; Presence of hepatic disease ; Presence of renal disease ; Presence of Endocrine disorders ; Presence of malabsorptive disorders ; Presence of cancer

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Primary 25-Hydroxy Vitamin D. Timepoint: Befor treatment. Method of measurement: ng/dl-laboratory kit.;Secondary 25-Hydroxy Vitamin D. Timepoint: 2-6 weeks after the end of treatment. Method of measurement: ng/dl-laboratory kit.	—

Secondary

Measure	Time frame
Secondary serum calcium. Timepoint: 2-6 weeks after end of treatment. Method of measurement: mg/dl-laboratory kit.;Primary urine calcium-creatinin ratio. Timepoint: before treatment. Method of measurement: laboratory kit.;Secondary urine calcium-creatinin ratio. Timepoint: 2-6 weeks after end of treatment. Method of measurement: laboratory kit.;Primary serum PTH. Timepoint: before treatment. Method of measurement: Pg/dl-laboratory kit.;Secondary serum PTH. Timepoint: 2-6 weeks after end of treatment. Method of measurement: Pg/dl-laboratory kit.;Primary serum calcium. Timepoint: before treatment. Method of measurement: mg/dl-laboratory kit.;Secondary serum phosphorus. Timepoint: 2-6 weeks after end of treatment. Method of measurement: mg/dl-laboratory kit.;Primary serum phosphorus. Timepoint: before treatment. Method of measurement: mg/dl-laboratory kit.;Primary serum alkaline phosphatase. Timepoint: before treatment. Method of measurement: Unit/l-laboratory kit.;Secondary serum alkaline phosphatase. Timepoint: 2-6 weeks after end of treatment. Method of measurement: Unit/l-laboratory kit.	—

Measure

Time frame

Secondary serum calcium. Timepoint: 2-6 weeks after end of treatment. Method of measurement: mg/dl-laboratory kit.;Primary urine calcium-creatinin ratio. Timepoint: before treatment. Method of measurement: laboratory kit.;Secondary urine calcium-creatinin ratio. Timepoint: 2-6 weeks after end of treatment. Method of measurement: laboratory kit.;Primary serum PTH. Timepoint: before treatment. Method of measurement: Pg/dl-laboratory kit.;Secondary serum PTH. Timepoint: 2-6 weeks after end of treatment. Method of measurement: Pg/dl-laboratory kit.;Primary serum calcium. Timepoint: before treatment. Method of measurement: mg/dl-laboratory kit.;Secondary serum phosphorus. Timepoint: 2-6 weeks after end of treatment. Method of measurement: mg/dl-laboratory kit.;Primary serum phosphorus. Timepoint: before treatment. Method of measurement: mg/dl-laboratory kit.;Primary serum alkaline phosphatase. Timepoint: before treatment. Method of measurement: Unit/l-laboratory kit.;Secondary serum alkaline phosphatase. Timepoint: 2-6 weeks after end of treatment. Method of measurement: Unit/l-laboratory kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Fatemeh Sayarifard

Tehran University of Medical Sciences, Children Medical Center

f-sayarifard@tums.ac.ir+98 21 6693 5848

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026